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To the Editor: We read with inter-
est the article, The Changing Epidemi-
ology of Leptospirosis in Israel,
published in volume 7, no. 6 (1). Lep-
tospirosis, a septicemic zoonosis with
multisystemic involvement, is caused
by the pathogenic strains of Lep-
tospira interrogans.  Rural farm work-
ers are at high risk for leptospirosis,
and it can be a significant public
health problem when water and food
safety are not ensured. Several epi-
demics of leptospirosis have occurred
on Andaman and Nicobar islands and
in southern and western parts of India
during the past century (2). The organ-
ism has been detected in farm animals
in many parts of the country (3); how-
ever, human infections have been
more or less localized. In 1998,
researchers warned that, unless ade-
quate public health measures were ini-
tiated, large leptospirosis epidemics
were possible in areas where the dis-
ease had not been previously reported
(4). In addition, they recommended
improving clinical diagnosis and con-
ducting systematic epidemiologic
studies for control of the disease (4).
The true incidence of human lep-
tospirosis in northern India is not
known either because of a lack of
awareness on the part of the treating
physicians or the lack of diagnostic
techniques. In 1966, human lep-
tospirosis was reported in Delhi, a
state in northern India (5). In a 1966
study (5), sera from persons with pyr-
exia and jaundice were tested by the
agglutination lysis test for leptospiral
antibodies. Of 93 serum specimens
from persons with pyrexia cases, 3
were positive (1 with L. icterohemor-
rhagica and two with L. canicola); of
43 serum specimens from persons
with jaundice, 3 were positive (2 with
L. icterohemorrhagica and 1 with L.
icterohemorrhagica and L. pomona).
No other study on leptospirosis has
been done in the region, and no data
are available concerning the problem.
To assess the current status of
transmission in Delhi and its adjoining
areas, we conducted a systematic
study for the diagnosis of leptospirosis
in our hospital from April 2000 to
March 2001; case definition criteria
suggested in a previous study (4) were
used. A case was defined as a person
with fever, headache, and myalgia and
more than two of the following symp-
toms: jaundice, oliguria, respiratory
symptoms (cough, hemoptysis, and
breathlessness), hemorrhagic manifes-
tations (hematemesis, bleeding gums,
and subconjunctival hemorrhage), and
signs of meningeal irritation and con-
vulsion. Seventy-five patients (44
male patients; 3–73 years of age) sat-
isfied the inclusion criteria. In addition
to clinical evaluation and assessment
for other diseases, leptospirosis was
investigated by the following labora-
tory methods: isolation of Leptospira
interrogans, direct visualization of the
organism under dark-field micros-
copy, and enzyme-linked immunosor-
bent assay (ELISA) for Leptospira
immunoglobulin (Ig) M antibody
(Serion Immunodiagnostica GmbH,
Würzburg, Germany). Per manufac-
turer’s specifications, the sensitivity,
specificity, positive predictive value,
and negative predictive value of this
kit are 96%, 97%, 90%, and 99%,
respectively). All blood samples were
sent to the Leptospira referral labora-
tory at the Indian Veterinary Research
Institute, Izzatnagar, for microscopic
agglutination test (MAT). Eight sero-
vars of L. interrogans ( australis,
autumnalis, pomona, sejroe, tarassovi,
icterohaemorrhagica, hebdomadis,
and patoc) were tested, and a aggluti-
nation titer of more than 1:100 was
considered positive. All patients were
treated empirically with broad-spec-
trum antibiotics as well as specific
drugs according to the results of inves-
tigations.
Thirty-two patients (42.6%) had a
positive ELISA test for Leptospira
IgM antibody. The results of MAT
were positive in 21 (65.6%) of the 32
ELISA-positive serum samples.
Serum specimens from 11 patients
reacted with a single serovar, and
specimens from 10 patients reacted
with more than one serovar. Among
the pathogenic species, Leptospira
antibodies were detectable by MAT
predominantly against L. sejroe (7 of
21), followed by L. icterohaemorrhag-
ica (6 of 21), L. hebdomadis (4 of 21),
and L. tarassovi (4 of 21). Leptospira
antibodies were also detectable
against L. autumnalis (3 of 21), L. aus-
tralis (2 of 21), and L. pomona (1 of
21). Against L. patoc, MAT could
detect antibodies in six samples. The
organism could not be isolated in cul-
ture or visualized under dark-field
microscopy in any of the specimens.
Of the 43 case-patients with ELISA-
negative specimens, alternative diag-
noses were established for 40 on the
basis of various laboratory investiga-
tions. In five of the patients with
ELISA-positive specimens, coinfec-
tion with other pathogens was
detected, including Salmonella typhi
(one case) by a positive Widal test,
hepatitis C virus by positive ELISA
(two cases), and Plasmodium falci-
parum (two cases) by a positive smear.
Five patients, including three who
were ELISA positive for Leptospira,
died. The highest number of ELISA-
positive serum samples (21 of 32)
were obtained in August and Septem-
ber 2000, suggesting an epidemic.
Epidemiologic investigation of
leptospirosis is often hampered by the
difficulty of making a definitive
microbiologic diagnosis. Isolation of
leptospira from clinical samples pro-
vides a definitive diagnosis; however,
the value of culture is limited because
samples have to be collected before
the administration of antibiotics, and
culturing requires prolonged incuba-
tion. Demonstration of typical motility
of leptospira under dark-ground illu-
mination in clinical samples, though
helpful in early diagnosis, has low
sensitivity and depends on the techni-
cian’s opinion. Measurement of IgM
antibodies against Leptospira by
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nostic test with good specificity and
sensitivity (6). The probability of
achieving a positive serologic test
increases with the duration of disease,
and good correlation between results
of MAT and ELISA has been reported
by Cumberland et al. (7). MAT has
emerged as a dependable diagnostic
tool for leptospirosis (next to isola-
tion) by providing serovar specific
diagnosis. However, a large number of
serovars of L. interrogans exist, and
maintaining large numbers of organ-
isms for MAT is difficult for most lab-
oratories. Moreover, MAT may fail to
detect antibodies when specific sero-
vars are not used. In this study, the
ELISA-positive samples, for which
MAT results were negative, may have
been caused by infection with serovars
other than those used in this study.
Because of the problems with meth-
ods, leptospirosis is grossly underdi-
agnosed.
Leptospira organisms require
humid weather for their survival.
Rodents and domestic animals (i.e.,
cattle and dogs) harbor leptospires and
shed the bacteria in urine; they may
disseminate the organism to rain water
and drinking water sources. Humans
frequently come in contact with con-
taminated water during floods; the
number of cases is higher during and
after heavy rainfalls. We found that
the peak incidence of the disease was
during August and September, the
monsoon season, which may explain
the high incidence of seropositivity
during this period. Though the organ-
ism has been detected in farm animals
in northern India, human leptospirosis
has not been considered a major pub-
lic health problem, probably because
transmission is low in arid weather
conditions. As a result of 13 consecu-
tive monsoons of above-average
strength in India, changes in the envi-
ronment may be promoting the trans-
mission of this organism. Recently,
two other regions in northern India,
Chandigarh (8) and Varanasi (9), have
reported a Leptospira seroprevalance
rate of 8.8% and 21.74%, respectively.
Our study supports the warning
from other researchers regarding the
threat of leptospirosis in areas such as
northern India. Preventive measures
should be initiated and rapid and
definitive diagnostic tests must be
developed. 
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